Document is current
Any future updates will be listed below
-
Authors
Seah, Michelle K. Y.
Han, Brenda Y. https://orcid.org/0000-0002-3212-875X
Huang, Yan https://orcid.org/0000-0003-4704-4767
Rasmussen, Louise J. H.
Stäubli, Andrina J.
Bello-RodrÃguez, Judith
Chan, Andrew Chi-Ho
Gasnier, Maxime
Wollmann, Heike
Guccione, Ernesto https://orcid.org/0000-0001-7764-5307
Messerschmidt, Daniel M. https://orcid.org/0000-0003-2022-4696
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD102385)
- License Information
-
More Information
Article History
Received: 12 June 2024
Accepted: 7 February 2025
First Online: 24 February 2025
Competing interests
: The Guccione laboratory received research funds from AZ and Prelude Therapeutics (for unrelated projects), E.G. is a cofounder and shareholder of Immunoa Pte.Ltd and cofounder, shareholder, consultant and advisory board member of Prometeo Therapeutics. The remaining authors declare no competing interests.
